Researchers have used mRNA technology to try to find an effective and safe vaccine against mpox.
An experimental vaccine from Moderna against MPOX has shown greater effectiveness than current vaccines in reducing symptoms and the duration of the disease, according to an animal study published September 4 in the journal CellThis announcement comes as Africa is experiencing a resurgence of MPOX, which with the appearance of a new variant (1b) prompted the World Health Organization (WHO) to trigger its highest level of global health alert on August 14.
Same technology for its coronavirus vaccine
Researchers used mRNA technology to try to find a vaccine against MPOX that would be highly effective and safe, virologist and lead author of the study Jay Hooper of the US Army Medical Research Institute of Infectious Diseases told AFP.
Vaccines against MPOX, formerly known as monkeypox, were originally developed to combat human smallpox, a deadly disease that was declared eradicated by the WHO in 1980. The vaccine currently marketed as Jynneos in the United States, Imvanex in Europe and Imvamune in Canada is made from a “live attenuated” virus, meaning the virus has been weakened so that it cannot transmit the disease to humans.
But being attenuated, it is also less protective than the older generation ACAM2000 vaccine, which is however not recommended for all audiences because of its side effects. Moderna’s new mRNA vaccine includes genetic instructions that train the immune system to recognize four antigens that allow the virus to attach to cells. The American laboratory uses the same technology for its coronavirus vaccine, which is very safe and effective.
Next tests on humans
In this study, six macaques were vaccinated with the mRNA vaccine, e[…]
- sciencesetavenir.fr
Also read
Related News :